AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for tRNA (adenine(58)-N(1))-methyltransferase, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9BVS5

UPID:

TR61B_HUMAN

Alternative names:

mRNA methyladenosine-N(1)-methyltransferase

Alternative UPACC:

Q9BVS5; Q9H0Q9; Q9NWS7

Background:

The tRNA (adenine(58)-N(1))-methyltransferase, mitochondrial, also known as mRNA methyladenosine-N(1)-methyltransferase, plays a crucial role in mitochondrial function. It catalyzes the formation of N(1)-methyladenine in various tRNAs within the mitochondrion, impacting tRNA(Leu), tRNA(Lys), and tRNA(Ser). This enzyme also modifies mitochondrial 16S ribosomal RNA, essential for mitoribosomal structure and function, and acts on MT-ND5 mRNA, affecting mitochondrial translation.

Therapeutic significance:

Understanding the role of tRNA (adenine(58)-N(1))-methyltransferase, mitochondrial could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.